Press Releases :: Algernon Pharmaceuticals Inc. (AGN)

Jan 14, 2022 8:15am EST

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

Jan 04, 2022 9:15am EST

Algernon Pharmaceuticals Issues Compensation Options

Dec 08, 2021 7:04am EST

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Dec 02, 2021 7:00am EST

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

Nov 30, 2021 7:00am EST

Algernon Pharmaceuticals Announces New Chief Financial Officer

Nov 24, 2021 7:00am EST

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

Nov 23, 2021 4:01pm EST

Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

Nov 19, 2021 7:00am EST

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Nov 17, 2021 4:14pm EST

Algernon Pharmaceuticals Announces Share Consolidation

Nov 01, 2021 7:00am EDT

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

arrow_back
1
2
3
4
5
6
7
8
9
10
…
18
arrow_forward

rss_feed News RSS

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company.

Sign up for our News Releases and Updates

Head Office

Suite 400 - 601 West Broadway
Vancouver, British Columbia V5Z 4C2

Follow Us On

© Algernon Pharmaceuticals Inc. - All Rights Reserved